Military gives Acorda $2.67M for test of spinal cord treatment

01/25/2013 | Genetic Engineering & Biotechnology News

The Army Medical Research and Material Command awarded Acorda Therapeutics a contract worth $2.67 million to support clinical development of AC105, a magnesium-based treatment, as a therapy for acute spinal cord injuries. The contract will support a midstage trial to evaluate AC105's safety and tolerability.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN